Bioptigen Inc. is an ISO 13485-certified medical device company that develops innovative ophthalmic imaging solutions. Bioptigen’s Envisu(tm) R-class systems are ideally suited to non-invasive ophthalmic imaging of animals ranging from zebrafish to elephants. Using low-power, near-infrared light, Envisu generates real-time, high-resolution, volumetric images of ocular microstructures from the cornea to the retina. Bioptigen has received CE approval to market its hand-held Envisu R2000 systems for preclinical use and C2000 systems for clinical use within the EU.
On June 8, 2015, Bioptigen was acquired by Leica Microsystems, a subsidiary of Danaher Corporation (NYSE: DHR).